Decoy-ACE2: Use of catalytically inactivated soluble ACE2 as anti CoVid19 drug
- Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
- Total publications:0 publications
Grant number: COV20_00437
Grant search
Key facts
Disease
COVID-19Funder
National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)Principal Investigator
Alberto Marina Moreno, Vicente Rubio ZamoraResearch Location
SpainLead Research Institution
Consorcio Centro de Investigación Biomédica en Red M.P. (CIBER)Research Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
2,3]). We will purify wild type or mutant ACE2 by affinity chromatography exploiting an artificial removable tag. We will prove that the mutant forms of ACE2 are catalytically inactive, stable, and that they bind to the binding region of the viral protein S. We will evaluate in cell cultures (collaboration with Jesús Rodríguez Díaz, Dept of Microbiology, Hospital Clínico-Universidad de Valencia) the potency of the mutated forms to inhibit the infection of viral inoculums. We will determine (crystallography or cryoEM) structures of mutant ACE / S binding domain complexes.